Mefloquine the drug's very long half-life, the Centers for Disease Control originally recommended a mefloquine dosage of 250 mg every two weeks; however, this caused an unacceptably high malaria rate in the Peace Corps volunteers who participated in the approval study, so the drug regimen was switched to once a week. The first randomized, controlled trial on a mixed population was performed in 2001. Prophylaxis with mefloquine was compared to prophylaxis with atovaquone-proguanil. Roughly 67% of participants in the mefloquine arm reported greater than or equal to one adverse event, vs 71% in the atovaquone-proguanil arm. In the mefloquine arm, 5%
International Association for the Treatment of Sexual Offenders either individual, couple, family, or even group settings. The treatments offered are created and used to prevent any offending behavior and further victimization of others. The biomedical treatment is the use of pharmacological treatment. This type of therapy in the past has included the use of anti-androgens, antidepressants, and anti-anxiety, anti epileptic, antipsychotic, or other types of medicine. However, note that biomedical treatment is not limited to these medications. All medications have different turnouts for different individuals, so it is crucial to find the best fit and the most successful medication for that specific person to help treat them and